Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadratus Lumborum Block for Total Hip Arthroplasty
NCT03408483Phase 3Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bupivacaine in pain (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Visual Analog Scale Pain Score at 48 hours and Opioid Consumption (Oral Morphine Equivalents) at 48 hours. Started Apr 2018; status: completed.
02
Drugs
bupivacaine
03
Conditions
pain
Beyond the preview
Go deeper on NCT03408483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408483.